VisualDx

Italy’s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has formed a partnership with US-based VisualDx. This alliance aims to enhance the identification of individuals who may have blastic plasmacytoid dendritic cell neoplasm (BPDCN) by introducing artificial intelligence/machine learning (AI/ML) tools. Understanding BPDCNBPDCN is an aggressive orphan hematologic malignancy with…